Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center

Leukemia

Volumn 28, Issue 6, 2014, Pages 1365-1368

  Stephens, D M ^a,b   Ruppert, A S ^b   Jones, J A ^a,b   Woyach, J ^a,b   Maddocks, K ^a,b   Jaglowski, S M ^a,b   Andritsos, L A ^a,b   Flynn, J M ^a,b   Grever, M R ^a,b   Lozanski, G ^a   Johnson, A J ^a,b   Muthusamy, N ^a,b   Heerema, N A ^a,b   Byrd, J C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; FLAVOPIRIDOL; IBRUTINIB; LACTATE DEHYDROGENASE; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR;

ADULT; AGED; APOPTOSIS; CANCER GROWTH; CHROMOSOME DELETION; CHROMOSOME DELETION 17P13; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 12; CLINICAL TRIAL (TOPIC); ELECTROCORTICOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE QUALITY; INSTITUTIONAL CARE; LYMPHOCYTOSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK FACTOR; TUMOR LYSIS SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

EID: 84902073992     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.42     Document Type: Letter

References (15)

1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
2. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986; 320: 84-85. (Pubitemid 16105254)
3. Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene 2008; 27: 6507-6521.
4. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331. (Pubitemid 27131374)
5. Wickremasinghe RG, Prentice AG, Steele AJ. p53 and Notch signaling in chronic lymphocytic leukemia: Clues to identifying novel therapeutic strategies. Leukemia 2011; 25: 1400-1417.
6. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458-1461.
7. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
8. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012-6018.
9. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404. (Pubitemid 46105932)
10. Muthusamy N, Breidenbach H, Andritsos L, Flynn J, Jones J, Ramanunni A et al. Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genet 2011; 204: 77-83.
11. Heerema NA, Byrd JC, Dal Cin PS, Dell'Aquila ML, Koduru PR, Aviram A et al. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxy nucleotide gives consistent karyotypic results among laboratories: A CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet 2010; 203: 134-140.
12. Shaffer L, Slovak M, Campbell L. ISCN 2009: An international system for human cytogentetic nomenclature 2009.
13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
14. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16: 219-242.
15. Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 2011; 25: 1444-1451.